Conflicts of interest in health care: Who guards the guardians?

Perspectives in Biology and Medicine

Volumn 50, Issue 1, 2007, Pages 72-88

  Epstein, Richard A ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROFECOXIB;

CONFLICT; DOCTOR PATIENT RELATION; DRUG INDUSTRY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE SYSTEM; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; UNIVERSITY;

EID: 33846604160     PISSN: 00315982     EISSN: None     Source Type: Journal    
DOI: 10.1353/pbm.2007.0002     Document Type: Review

References (35)

1. American Association of Health Plans (AAHP). 1999. Enrollment, growth, accreditation. http://www.ahip.org/content/default.aspx?bc=41|331|358.
2. Angell, M. 2004. The truth about the drug companies: How they deceive us and what to do about it. New York: Random House.
3. Armstrong, D. 2006. Bitter pill: How the New England Journal missed the warning signs on Vioxx. Wall Street J, May 15.
4. Bombardier, C., et al. 2006. Response to expression of concern regarding VIGOR study. N Engl J Med 354(11):1196-99.
5. Brennan, T. A., et al. 2006. Health industry practices that create conflicts of interest: A policy proposal for academic medical centers. JAMA 295:429-33.
6. Brophy v. New England Sinai Hosp., Inc., 497 N.E.2d 626 (Mass. 1986).
7. Canterbury v. Spence, 464 F.2d 772 (D.C. Cir. 1972).
8. Curfman, G. D., S. Morrissey, and J. M. Drazen 2005. Expression of concern: Bombardier et al., comparison of upper gastrointestinal toxicity of Rofecoxib and Naproxen in patients with rheumatoid arthritis. N Engl J Med 353(26):2813-14.
9. Curfman, G. D., S. Morrissey, and J. M. Drazen. 2006. Expression of concern reaffirmed. N Engl J Med 354(11):1193.
10. Drazen, J. M. 2006. Letter to the editor. Hidden data confounds medical journal editors. Wall Street J, May 19.
11. Epstein, R. A. 1986. On drafting rules and procedures for academic fraud. Minerva 24(2-3):344-47.
12. Epstein R. A. 2005a. Pharma furor: Why two high-profile attacks on big drug companies flunk the test of basic economics. Legal Affairs (Jan.-Feb.):60-63.
13. Epstein, R. A. 2005b. Regulatory paternalism in the market for drugs: Lessons from Vioxx and Celebrex. Yale J Health Policy Law Ethics 5(2):741-70.
14. Epstein, R. A. 2006a. Altruism and barter. National Law J (May 8):27.
15. Epstein, R. A. 2006b. Overdose: How excessive government regulation stifles pharmaceutical innovation. New Haven: Yale Univ. Press.
16. C.F.R. § 5501.109(c) (2006).
17. Freudenheim, M. 1998. (Loosely) managed care is in demand: Provider plans zooming over restrictive H.M.O.'s. NY Times, Sept. 29.
18. Guth v. Loft, Inc., 5 A.2d 503, 510 (Del. Ch. 1939).
19. Hamburger, P. 2004. The new censorship: Institutional review boards. Supreme Court Rev 271-354.
20. Hu, J. 2005. NEJM v. Merck. Blogs for Industry. http://dimer.tamu.edu/simplog/archive. php?blogid=3&pid=2963.
21. International Committee of Medical Journal Editors (ICMJE). 2006. Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication http://www.icmje.org/icmje.pdf.
22. Jensen, M. C., and W. H. Mecking. 1976. Theory of the firm: Managerial behavior, agency costs and ownership structure. J Financial Econ 3:305-60.
23. Kassirer, J. P. 2004. On the take: How medicine's complicity with big business can endanger your health. New York: Oxford Univ. Press.
24. Lowe, D. 2005. A Vioxx bomb drops. Or does it? In the Pipeline. http://www.corante. com/pipeline/archives/2005/12/09/ a_vioxx_bomb_drops_or_does_it.php.
25. National Institutes of Health (NIH). 2006. Conflict of interest information and resources. http://www.nih.gov/about/ethics_COI.htm.
26. Reicin, A., and D. Shapiro. 2006. Response to expression of concern regarding VIGOR study. N Engl J Med 354(11):1198.
27. Relman, A. S. 1978. The Saikewicz decision: Judges as physicians. N Engl J Med 298(9):508-9.
28. Rubin, P. H. 2004. Pharmaceutical marketing: Medical and industry biases. J Pharma Finance Econ Policy 13(2):65-79.
29. Sidaway v. Bd. of Governors of the Bethlem Royal Hosp., (1985) A.C. 871 (H.L.).
30. Steele v. Louisville & Nashville R.R., 323 U.S. 192, 203-204 (1944).
31. Stossel, T. P. 2005. Regulating academic-industrial research relationships: Solving problems or stifling progress? N Engl J Med 353:1060-65.
32. Superintendent of Belchertown State School v. Saikewicz, 370 N.E.2d 417, 435 (Mass. 1977).
33. University of Chicago Institutional Review Board. 2006. Frequently asked questions. http://ors.bsd.uchicago.edu/IRB/FAQ.html.
34. Wadman, M. 2005. Journal grows suspicious of Vioxx data. Nature 438(7070):899.
35. Wazana, A. 2000. Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA 283(3):373-80.